AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPEDIMED LTD

0.018

+0.00320.00%

Volume:9.69M

Turnover:159.02K

Market Cap:36.67M

PE:-1.56

High:0.018

Open:0.016

Low:0.016

Close:0.015

52wk High:0.059

52wk Low:0.015

Shares:2.04B

Float Shares:1.84B

Volume Ratio:1.05

T/O Rate:0.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.012

EPS(LYR):-0.012

ROE:-75.89%

ROA:-32.44%

PB:1.79

PE(LYR):-1.56

Loading ...

Overview Company News Filings

SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

BRIEF-ImpediMed Posts Q2 FY26 Revenue Of A$3.9 Million

ImpediMed Ltd - Q2 FY26 Revenue of a$3.9 Mln

THOMSON REUTERS

ImpediMed Ltd-Update - Application for Quotation of Securities - Ipd

THOMSON REUTERS

ImpediMed Says Reimbursement Supported by Increased Insurance Coverage for Lymphoedema Testing using Bioimpedance Spectroscopy

MT Newswires Live

BRIEF-ImpediMed Posts Qtrly Revenue Of A$3.6 Million

ImpediMed Says US Insurer Recognizes Lymphedema Screening Technology as Medically Necessary; Shares Rise 19%

MT Newswires Live

BRIEF-ImpediMed Posts FY Loss After Tax Of A$23.2 Million

ImpediMed Ltd - FY Revenue a$12.7 Mln

THOMSON REUTERS

ImpediMed Ltd - FY Loss After Tax a$23.2 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IPD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IPD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IPD.AU\",,,,,undefined,":{"symbol":"IPD.AU","market":"AU","secType":"STK","nameCN":"IMPEDIMED LTD","latestPrice":0.018,"timestamp":1770688701960,"preClose":0.015,"halted":0,"volume":9690767,"delay":0,"changeRate":0.19999999999999996,"nameEN":"IMPEDIMED LTD","floatShares":1840167408,"shares":2037429268,"eps":-0.011508,"marketStatus":"Trading","change":0.003,"latestTime":"02-10 12:59:00 AEDT","open":0.016,"high":0.018,"low":0.016,"amount":159017,"amplitude":0.133333,"askPrice":0.018,"askSize":517052,"bidPrice":0.017,"bidSize":1843683,"shortable":3,"etf":0,"ttmEps":-0.011508,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.015,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":1.054666,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IPD.AU\",,,,,undefined,":{"symbol":"IPD.AU","floatShares":1840167408,"roa":"-32.44%","roe":"-75.89%","lyrEps":-0.011508,"volumeRatio":1.054666,"shares":2037429268,"dividePrice":0,"high":0.018,"amplitude":0.133333,"preClose":0.015,"low":0.016,"week52Low":0.015,"pbRate":"1.79","psRate":"2.88","week52High":0.059,"institutionHeld":0,"latestPrice":0.018,"committee":0.561957,"eps":-0.011508,"divideRate":0,"volume":9690767,"delay":0,"ttmEps":-0.011508,"open":0.016,"prevYearClose":0.034,"prevWeekClose":0.019,"prevMonthClose":0.023,"prevQuarterClose":0.034,"fiveDayClose":0.02,"twentyDayClose":0.034,"sixtyDayClose":0.037,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPD.AU\",params:#limit:5,,,undefined,":[{"date":"2026-01-28","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1769554800000,"name":null,"time":"","dateTimestamp":1769518800000,"actualEps":null},{"date":"2025-10-29","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761692400000,"name":null,"time":"","dateTimestamp":1761656400000,"actualEps":null},{"date":"2025-07-31","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1753920000000,"name":null,"time":"","dateTimestamp":1753884000000,"actualEps":null},{"date":"2025-04-30","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745971200000,"name":null,"time":"","dateTimestamp":1745935200000,"actualEps":null},{"date":"2025-01-31","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1738278000000,"name":null,"time":"","dateTimestamp":1738242000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607773516","title":"SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family","url":"https://stock-news.laohu8.com/highlight/detail?id=2607773516","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607773516?lang=en_us&edition=fundamental","pubTime":"2026-01-29 10:10","pubTimestamp":1769652600,"startTime":"0","endTime":"0","summary":"Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family. Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology. SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine strategy centered on universal vaccines for future pandemic preparedness. SK bioscience aims to develop a universal vaccine capable of inducing broad immune responses across the entire virus family and is establishing a platform applicable to multiple related viruses and variants.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2872245/Photo_1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2872245/Photo_1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sk-bioscience-initiates-international-phase-12-clinical-trial-of-universal-vaccine-candidate-targeting-sarbecovirus-family-302673365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4075","IPD.AU","BK7007","BK7509","UVV","CEPI"],"gpt_icon":0},{"id":"2607720411","title":"BRIEF-ImpediMed Posts Q2 FY26 Revenue Of A$3.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2607720411","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607720411?lang=en_us&edition=fundamental","pubTime":"2026-01-29 09:32","pubTimestamp":1769650364,"startTime":"0","endTime":"0","summary":"BRIEF-ImpediMed Posts Q2 FY26 Revenue Of A$3.9 MillionJan 29 (Reuters) - ImpediMed Ltd IPD.AX:Q2 FY26 REVENUE OF A$3.9 MILLIONFurther company coverage: IPD.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT194:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","BK7509","IPD.AU"],"gpt_icon":0},{"id":"2607283247","title":"ImpediMed Ltd - Q2 FY26 Revenue of a$3.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2607283247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607283247?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:19","pubTimestamp":1769635146,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT194:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","IPD.AU","BK7007"],"gpt_icon":0},{"id":"2603250952","title":"ImpediMed Ltd-Update - Application for Quotation of Securities - Ipd","url":"https://stock-news.laohu8.com/highlight/detail?id=2603250952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603250952?lang=en_us&edition=fundamental","pubTime":"2026-01-16 14:23","pubTimestamp":1768544609,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUE4SLLJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","IPD.AU","BK7509"],"gpt_icon":0},{"id":"2588107167","title":"ImpediMed Says Reimbursement Supported by Increased Insurance Coverage for Lymphoedema Testing using Bioimpedance Spectroscopy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588107167","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588107167?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:21","pubTimestamp":1764814869,"startTime":"0","endTime":"0","summary":"ImpediMed  said reimbursement for lymphoedema testing using its SOZO Digital Health Platform was supported by a further three US state-based insurers and one multi-state insurer, taking measures recognizing bioimpedance spectroscopy as medically necessary for the assessment of lymphoedema, according to a Thursday Australian bourse filing.This led to the total covered lives increasing to 314.5 million from 304 million, per the filing.The firm's shares rose 1% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7509","IPD.AU","BK7007"],"gpt_icon":0},{"id":"2579525421","title":"BRIEF-ImpediMed Posts Qtrly Revenue Of A$3.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2579525421","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579525421?lang=en_us&edition=fundamental","pubTime":"2025-10-30 09:26","pubTimestamp":1761787594,"startTime":"0","endTime":"0","summary":"BRIEF-ImpediMed Posts Qtrly Revenue Of A$3.6 MillionOct 30 (Reuters) - ImpediMed Ltd IPD.AX:QTRLY REVENUE OF A$3.6 MILLIONFurther company coverage: IPD.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUERWQ4D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPD.AU","BK7007","BK7509"],"gpt_icon":0},{"id":"2572955715","title":"ImpediMed Says US Insurer Recognizes Lymphedema Screening Technology as Medically Necessary; Shares Rise 19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572955715","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572955715?lang=en_us&edition=fundamental","pubTime":"2025-10-02 12:31","pubTimestamp":1759379477,"startTime":"0","endTime":"0","summary":"ImpediMed  said a US-health insurer has recognized the company's bioimpedance spectroscopy technology as medically necessary to assess lymphedema, according to a Thursday filing with the Australian bourse.The recognition will support reimbursement for lymphedema testing using the company's digital health platform, the filing said.Shares of the company rose 19% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7509","XJO.AU","IPD.AU","BK7007","XKO.AU","XAO.AU"],"gpt_icon":0},{"id":"2562283708","title":"BRIEF-ImpediMed Posts FY Loss After Tax Of A$23.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562283708","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562283708?lang=en_us&edition=fundamental","pubTime":"2025-08-28 10:14","pubTimestamp":1756347264,"startTime":"0","endTime":"0","summary":"BRIEF-ImpediMed Posts FY Loss After Tax Of A$23.2 MillionAug 28 (Reuters) - ImpediMed Ltd IPD.AX:FY LOSS AFTER TAX A$23.2 MILLIONFY REVENUE A$12.7 MILLIONFurther company coverage: IPD.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UJ0JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPD.AU","BK7509","BK7007"],"gpt_icon":0},{"id":"2562953775","title":"ImpediMed Ltd - FY Revenue a$12.7 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562953775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562953775?lang=en_us&edition=fundamental","pubTime":"2025-08-28 06:18","pubTimestamp":1756333106,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ0JA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","BK7007","IPD.AU"],"gpt_icon":0},{"id":"2562577595","title":"ImpediMed Ltd - FY Loss After Tax a$23.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562577595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562577595?lang=en_us&edition=fundamental","pubTime":"2025-08-28 06:18","pubTimestamp":1756333106,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ0JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IPD.AU","BK7509","BK7007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}